Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro.
J Thromb Haemost
; 21(1): 76-82, 2023 01.
Article
en En
| MEDLINE
| ID: mdl-36695399
ABSTRACT
BACKGROUND:
Central venous catheters are prone to clotting, particularly in patients with cancer. Although low-molecular-weight heparin and direct oral anticoagulants, such as apixaban and rivaroxaban, have been evaluated for the prevention of catheter thrombosis, their efficacy remains uncertain.OBJECTIVES:
Compare apixaban and rivaroxaban with enoxaparin for the prevention of catheter-induced clotting in vitro.METHODS:
To address this uncertainty, we used a well-established microplate-based assay to compare the effects of enoxaparin, apixaban, and rivaroxaban on catheter-induced thrombosis and thrombin generation in human plasma.RESULTS:
Consistent with our previous findings, catheter segments shortened the clotting time and promoted thrombin generation. When compared at concentrations with similar anti-factor Xa activity as enoxaparin, apixaban and rivaroxaban were >20-fold less potent than enoxaparin for the prevention of catheter-induced clotting and thrombin generation.CONCLUSION:
The prevention of catheter thrombosis in patients with cancer is challenging. Clinical trials are needed to compare the efficacy of low-molecular-weight heparin with that of direct oral anticoagulants both for the prevention and treatment of catheter thrombosis.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Trombosis
/
Neoplasias
Tipo de estudio:
Etiology_studies
Idioma:
En
Revista:
J Thromb Haemost
Asunto de la revista:
HEMATOLOGIA
Año:
2023
Tipo del documento:
Article